The start of the New Year is a good time for making predictions, so here is one: look for the US Food & Drug Administration to start convening advisory committees more frequently once the new team takes over under President-Elect Joe Biden.
FDA held just 18 reviews of pending new drug applications in 2020, the fewest since 2007. (Arguably it was even...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?